Research Directions Depression
October 13, 2023
Ian B. Hickie, F. Markus Leweke, Allan H. Young
1 citation
In recent years, there has been considerable enthusiasm among research groups focused on developing novel therapies for treatment-resistant depression, and a wider community that has had experiences using recreational drugs, in more systematic evaluation of the therapeutic value of these compounds (Goodwin et al., 2022; Young, 2023). This has also been associated with advocacy for...
Scientific Reports
October 11, 2023
Sven Wasserthal, Mirko Lehmann, Claudia Neumann et al.
7 citations
Schizophrenia is associated with various deficits in social cognition that remain relatively unaltered by antipsychotic treatment. While faulty glutamate signaling has been associated with general cognitive deficits as well as negative symptoms of schizophrenia, no direct link between manipulation of glutamate signaling and deficits in mentalizing has been demonstrated thus far. Here, we...
Frontiers in Psychiatry
October 9, 2023
Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, S. Joshi et al.
6 citations
Introduction Subanesthetic ketamine is a rapidly acting antidepressant that has also been found to improve neurocognitive performance in adult patients with treatment resistant depression (TRD). Provisional evidence suggests that ketamine may induce change in hippocampal volume and that larger pre-treatment volumes might be related to positive clinical outcomes. Here, we examine the effects of...
Research Square
October 3, 2023
Christopher Pittenger, Cheng Jiang, Ralph Dileone et al.
preprint
Recent studies have implicated the endogenous opioid system in the antidepressant actions of ketamine, but the underlying mechanisms remain unclear. We used a combination of pharmacological, behavioral, and molecular approaches in rats to test the contribution of the prefrontal endogenous opioid system to the antidepressant-like effects of a single dose of ketamine. Both the behavioral actions...
European Archives of Psychiatry and Clinical Neuroscience
October 2023
Elifrances Galdino de Oliveira, Diógenes Afonso De Lima, José Carlos Da Silva Júnior et al.
Infections during pregnancy are associated with an increased risk of neuropsychiatric disorders with developmental etiologies, such as schizophrenia and autism spectrum disorders (ASD). Studies have shown that the animal model of maternal immune activation (MIA) reproduces a wide range of phenotypes relevant to the study of neurodevelopmental disorders. Emerging evidence shows that (R)-ketamine...
British Journal of Anaesthesia
October 2023
Jordan J Wehrman, Cameron P Casey, Sean Tanabe et al.
Sensory disconnection is a key feature of sleep and anaesthesia. We have proposed that predictive coding offers a framework for understanding the mechanisms of disconnection. Low doses of ketamine that do not induce disconnection should thus diminish predictive coding, but not abolish it. Ketamine was administered to 14 participants up to a blood concentration of 0.3 μg ml-1 Participants were...
Pharmacology, Biochemistry, and Behavior
October 1, 2023
Talita Rodrigues, Getulio Nicola Bressan, Barbara Krum et al.
Schizophrenia is a chronic, debilitating mental illness that has not yet been completely understood. In this study, we aimed to investigate the effects of different doses of ketamine, a non-competitive NMDA receptor antagonist, on the positive- and negative-like symptoms of schizophrenia. We also explored whether these effects are related to changes in the immunoreactivity of GAD67, TH, and...
Cannabis and Cannabinoid Research
October 1, 2023
Pedro Henrique Gobira, Jacob LaMar, Jade Marques et al.
Introduction: The antidepressant properties of ketamine have been extensively demonstrated in experimental and clinical settings. However, the psychotomimetic side effects still limit its wider use as an antidepressant. It was recently observed that endocannabinoids are inolved in ketamine induced reward properties. As an increase in endocannabinoid signaling induces antidepressant effects,...
Brain, Behavior, and Immunity
October 1, 2023
Xinying Zhang, Teng He, Zifeng Wu et al.
CD38 is involved in immune responses, cell proliferation, and has been identified in the brain, where it is implicated in inflammation processes and psychiatric disorders. We hypothesized that dysfunctional CD38 activity in the brain may contribute to the pathogenesis of depression. To investigate the underlying mechanisms, we used a lipopolysaccharide (LPS)-induced depression model and...
The Lancet Psychiatry
October 1, 2023
Gustavo C Medeiros, Malcolm Matheson, Isabella Demo et al.
38 citations
Ketamine is an effective antidepressant, but there is substantial variability in patient response and the precise mechanism of action is unclear. Neuroimaging can provide predictive and mechanistic insights, but findings are limited by small sample sizes. This systematic review covers neuroimaging studies investigating baseline (pre-treatment) and longitudinal (post-treatment) biomarkers of...